History

The Kirov Branch of JSC "AVVA RUS" has received GMP certification from the Republic of Cyprus.

JSC "AVVA RUS," a pharmaceutical company included in the list of systemically important enterprises of the Kirov Region, underwent an audit at the end of 2023 by the drug supervision and control authorities of the Republic of Cyprus for compliance with Good Manufacturing Practice (GMP). It has now received official confirmation of successfully passing the inspection, honored with the corresponding certificate.

Thus, JSC "AVVA RUS" has once again undergone the GMP certification procedure, confirming the highest quality of its manufactured products and their recognition at the international level.

JSC "AVVA RUS" has registered its production site located at Russia, Kirov, Lugnanskaya 53A in the UAE, which grants the right to supply medicines to the UAE market.

AVVA RUS has successfully passed an audit by the Saudi FDA for compliance with GMP standards

AVVA RUS JSC received the European GMP EU certificate.

AVVA RUS JSC concluded an agreements for supplying of products in Mongolia.

AVVA RUS started the registration of medicine in Turkmenistan.

The drug Ecofuril received the Green Cross International Pharmaceutical Award in the nomination “Balance in the treatment of diarrhea and restoration of microflora”.

Launch of a new packaging line in production.

AVVA RUS JSC has concluded Agreements with companies in Georgia and Kyrgyzstan for the supplying of medicine.

AVVA RUS JSC has successfully passed recertification for compliance of the quality management system with the requirements of ISO 9001-2015.

The line for the production of pellets and powders in sachets was launched.

The organizational form of the enterprise JSC AVVA RUS is being changed. Production is constantly being improved, with enhancements not only to the factory building facades but also to the access roads and pathways. The production line is being automated. The production of suppositories and LDFs (liquid dosage forms) has been launched.

A strategic marketing agreement was concluded with OJSC Farmstandart on joint promotion of the medical products like Micrazim, Lactofiltrum, Filtrum, Ursoliv, Dinolac on the Russian market.

Medical drug Ursoliv and ecoantibiotic were started to market in the Russian Federation and in the CIS.

Pharmaceutical company AVVA RUS was founded. Both AVVA RUS and the Swiss company AVVA Pharmaceutical AG are included in the group. The company AVVA Ukraine and the representative office in the Republic of Uzbekistan AVVA Uzbekistan were established.

Work has begun in collaboration with AVVA Pharmaceuticals AG on the development and registration of Eco-antibiotic drugs. A central factory laboratory structure has been established for the development of new pharmaceuticals.

The production of "STI-MED-SORB" is being certified by the Russian Ministry of Health and Social Development in accordance with the requirements of OST 42-510-98 and is being reorganized into JSC AVVA RUS, which is part of a pharmaceutical holding together with the Swiss company AVVA Pharmaceuticals AG.

Technological lines for the production of various forms of medical products are being created.

Tablet production is expanding. The production of branded products "Filtrum" and "Lactofiltrum" is being established.

Launching the production of betalactam antibiotics.

Creation of pharmaceutical group Leksir comprising:

• Leksir – engineering and marketing company which is also the group managing company (located in Moscow);
• Leksir Ukraine – the representative office.

Creation of a technological line for the production of various forms of medical products.

STI-MED-SORB begins modernization and reconstruction of the enterprise to GMP standards.

The first drugs produced under its own brand name were Polyphepan and Polyphan enteric sorbents based on hydrolysis lignin. At the same time, the company is developing a new line of business: the supply of imported substances to plants along with scientific and technological documentation and know-how.

Establishment of the pharmaceutical company "Sti-Medsorb" in Kirov. Development of the production of hydrolytic lignin substance and finished dosage forms based on it at the STI-MED-SORB plant, Kirov. Lignin is a natural enterosorbent that can effectively remove harmful toxins from the body.